How brief bursts of DUX4 change muscle in FSHD
To explore the molecular and cellular effects of transient DUX4 expression in skeletal muscle
Researchers are looking at whether short, low-level bursts of the DUX4 protein can cause lasting muscle damage in people with facioscapulohumeral muscular dystrophy (FSHD).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11146473 on NIH RePORTER |
What this research studies
This work uses a special inducible mouse model that can turn DUX4 on and off in muscle fibers to mimic what may happen in FSHD. Scientists will give controlled, transient pulses of DUX4 and then follow the muscles over time to see lasting changes in tissue structure, scarring, and supporting cell types. They will measure how muscles recover after injury, track increases in fibrotic matrix and fibro-adipogenic progenitors, and examine epigenetic changes that may lock in damage. The aim is to understand why brief DUX4 expression might prime muscle for long-term problems and point to ways to prevent or reverse that process.
Who could benefit from this research
Good fit: Adults with genetically confirmed FSHD who might consider contributing clinical data or tissue samples to related translational studies would be most relevant.
Not a fit: People without FSHD or those with very advanced, irreversible muscle loss are unlikely to receive direct short-term benefit from this basic-mechanism work.
Why it matters
Potential benefit: If successful, this could identify when and how to block DUX4-driven damage and suggest targets or timing for therapies to prevent permanent muscle loss in FSHD.
How similar studies have performed: Previous mouse-model studies and patient biopsy data have hinted that transient DUX4 can leave lasting changes, but translating that to patient treatments is still novel and not yet proven.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Bosnakovski, Darko — University of Minnesota
- Study coordinator: Bosnakovski, Darko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.